Welcome Frederik Ziebell

Frederik has a PhD in Applied Mathematics from Heidelberg University and the German Cancer Research Center (DKFZ). He works on developing statistical methods for high-dimensional heterogeneous data and the analysis of multi-omic level drug treatment effects in collaboration with Cellzome.

Welcome Almut Lütge

Almut is a master student in molecular biotechnology at the University of Heidelberg. She joined the Huber group in 2017 and works on the analysis of RNA-seq data from Chronic lymphatic leukemia (CLL) samples.

Welcome Arne Smits

Arne has a PhD degree from the Radboud University (Nijmegen, The Netherlands). His previous research in the laboratory of Prof. Michiel Vermeulen focused on the identification and quantification of protein-protein and DNA-protein interactions using quantitative proteomics. As a EIPOD postdoctoral fellow at EMBL, he is studying the systems-wide effects of drug treatment in collaboration with Cellzome and the Steinmetz group.

Congratulations Sophie Rabe

Sophie studied Molecular Biotechnology at the University of Heidelberg. She joined the Huber Group in Spring 2014 as student research assistant and worked on genomic biomarkers of drug sensitivity in primary blood cancer cells. For her PhD thesis, Sophie is now joining the group of Sascha Dietrich at NCT Heidelberg, where she will work on the SYMPATHY project, an integrated system medicine approach to personalized and targeted therapy in leukaemia and lymphoma. This multidisciplinary project is intended to have direct clinical impact on patient care in blood cancers.

Welcome Karsten Bach

Karsten Bach has a B.Sc. in Biology from the University of Bonn. He joined the Huber group in March 2016. At EMBL, he is finishing up his M.Sc. in Molecular Biotechnology and working on quantitative proteomics together with Dorothee Childs and Nikos Ignatiadis.

Presentation by Dorothee

Dorothee Childs presented her work at the EMBL-Wellcome Genome Campus Conference “Target Validation using Genomics and Informatics 2015″, which took place from 8th to 10th December 2015 in Cambridge.
More than 200 people attended this ground-breaking conference. Dorothee gave a talk on “Screening for drug targets in intact cells by thermal proteome profiling”, a project in which she is involved as part of a collaboration between EMBL Heidelberg and GSK’s SME Cellzome, which is also based in Heidelberg.”

thumb_IMG_0110_1024

thumb_IMG_0102_1024 2

thumb_IMG_0109_1024

Welcome Annika

Annika Gable has a B.Sc. in Molecular Biotechnology from the University of Heidelberg. She joined the Huber group in December 2015. At EMBL, she is finishing up her M.Sc. in Molecular Biotechnology (major: Bioinformatics) with a thesis on analyzing high-throughput chromatin conformation capture (Hi-C) data.